Skip to main content
. 2022 Apr 8;7(7):e151596. doi: 10.1172/jci.insight.151596

Figure 6. Loss of Ccr2 in HTx recipients abrogates the effects of FAO inhibition.

Figure 6

(A) Comparison of graft survival in vehicle-treated (ctrl-treated) or etomoxir-treated (eto-treated) BALB → B6 CCR2–/– heart allografts. There was no statistical difference in survival (P = 0.7698 by Mantel-Cox test). (B–E) Flow cytometric assessment in BALB → Ccr2–/– heart allografts 4 days after transplant, shown as a percentage of CD45+ cells (left graph) or live cells (right graph; data for live cells from BALB → B6 HTx is replotted from Figures 1 and 2). (B) Pan T cells assessed by CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB B6 Ccr2–/– HTx). (C) Activated T cells assessed by CD69+CD3+CD90.2+ cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB →B6 Ccr2–/– HTx). (D) DCs assessed by CD11c+MHCII+CD64– cells (ctrl, n = 5; eto, n = 5 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB B6 Ccr2–/– HTx). (E) Macrophages assessed by CD11b+CD64+CD24– cells (ctrl, n = 8; eto, n = 7 for BALB → B6 HTx; ctrl, n = 3; eto, n = 3 for BALB → B6 Ccr2–/– HTx). (F) ELISPOT assay performed using splenocytes procured 4 days after transplantation from ctrl or eto-treated BALB B6 Ccr2–/– heart allografts. Samples were stimulated with donor-derived (BALB) APCs and assessed for the production of IFN-γ (ctrl, n = 5; eto, n = 5). Data are shown as mean ± SEM. *P < 0.05; **P < 0.01; ****P < 0.0001 (B–E, left graphs, and F) by t test or (B–E, right graphs) ANOVA and Bonferroni’s post hoc test.